Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma

Peter E. Fecchi, Duane A. Mitchell, John F. Whitesides, Weihua Xie, Allan H. Friedman, Gary E. Archer, James H. Herndon II, Darell D. Bigner, Glenn Dranoff, and John H. Sampson

Abstract

Immunosuppression is frequently associated with malignancy and is particularly severe in patients with malignant glioma. Anergy and counterproductive shifts toward Th2 cytokine production are long-recognized T-cell defects in these patients whose etiology has remained elusive for >30 years. We show here that absolute counts of both CD4+ T cells and CD4+CD25+FOXP3+CD45RO+ T cells (Tregs) are greatly diminished in patients with malignant glioma, but Tregs frequently represent an increased fraction of the remaining CD4 compartment. This increased Treg fraction, despite reduced counts, correlates with an inability to elicit the characteristic manifestations of impaired patient T-cell responsiveness in vitro. Furthermore, Treg removal eradicates T-cell proliferative defects and reverses Th2 cytokine shifts, allowing T cells from patients with malignant glioma to function in vitro at levels equivalent to those of normal, healthy controls. Such restored immune function may give license to physiologic antitumor activity, as in vivo, Treg depletion proves permissive for spontaneous tumor rejection in a murine model of established intracranial glioma. These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for Tregs in facilitating tumor immune evasion in the central nervous system. (Cancer Res 2006; 66(6): 3294-302)

Introduction

Patients with malignant glioma exhibit a comprehensive depression in cellular immune function that has been documented for more than three decades (reviewed in ref. 1). Although malignant gliomas remain within the intracranial compartment and rarely metastasize, immunosuppression in patients is both systemic and profound. Deficiencies in T-cell function are especially well-documented and patient lymphocytes respond poorly to T-cell mitogens, anti-CD3 monoclonal antibody, and T-dependent B-cell mitogens (2, 3). Although present, neither lymphopenia nor immunosuppressive factors present in the sera of patients entirely explain these deficits, as purified T cells retain a significant degree of nonresponsiveness even when cultured in normal sera (4, 5). A substantial measure of dysfunction is therefore intrinsic to the T-cell compartment. More specifically, this dysfunction seems manifest within the CD4+ T-cell subset (6), whose relative anergy is characterized most broadly by weakened proliferative responses and insufficient synthesis of the Th1 cytokine interleukin 2 (IL-2; refs. 7, 8). Production of other Th1-type cytokines also suffers, whereas Th2-type cytokines are typically elaborated at elevated levels (9, 10). The etiology of these T-cell proliferative defects and Th2 cytokine shifts remains poorly understood.

We noted that the cellular immune defects delineated for patients with malignant glioma show remarkable overlap with the typical consequences of regulatory T-cell (Tregs) activity. Tregs are a physiologic subset of CD4+ T cells expressing high levels of CD25 (IL-2Rα; ref. 11), and they potently inhibit T-cell activation and proliferation. Some of this is achieved through down-regulation of IL-2 production in their target cells (12), a predilection that recapitulates a central component of the T-cell anergy observed in patients with malignant glioma (7, 8). Tregs also inhibit IFN-γ production (13, 14) and prompt target cells to secrete predominantly Th2 cytokines (15), which can propagate the regulatory phenotype (16, 17). Tregs may elicit tolerance to tumor antigens and supraphysiologic Treg fractions have been found in the peripheral blood and tumors of patients with a variety of cancers (18–21).

We examine the contribution made by Tregs to depressed cellular immunity in patients with glioblastoma multiforme (GBM), the most common and malignant form of malignant glioma. We find that Tregs are actually reduced in absolute number in these patients who exhibit a substantial reduction in the number of circulating CD4+ T cells. Tregs, however, come frequently to represent an increased fraction of the remaining CD4 compartment. Patients with increased Treg fractions are those that show diminished lymphocyte responsiveness in vitro, and increasing Treg fractions among normal lymphocytes to such elevated levels proves sufficient to elicit the same impairments. Most importantly, removal of Tregs in vitro eradicates the differences in responsiveness observed among CD4+ T cells isolated from patients and healthy volunteers and reverses the predilection toward Th2 cytokine production.

Together, these results indicate that patient CD4+ T cells are capable of normal immune function, but are instead hindered by increased fractions of which seem necessary and sufficient to produce much of the “intrinsic” T-cell dysfunction in patients with GBM. Restored normal immune function may consist of physiologic antitumor activity, as the depletion of Tregs in vivo leads frequently to spontaneous tumor rejection in a murine model of intracranial glioma. These data dramatically alter our approach toward understanding and addressing depressed cellular immune function in patients with GBM.
Materials and Methods

Human samples. All samples were obtained at Duke University Medical Center from individuals who had given written, informed consent. Histopathologic diagnoses were established by the Department of Pathology. Those eligible underwent 4-hour leukapheresis at the Duke Apheresis Unit to obtain peripheral blood mononuclear cells (PBMC). All studies were done with approval of the institutional review board.

Fluorescence-activated cell sorting analysis of whole blood. Whole blood was incubated at room temperature for 15 minutes with combinations of titrated antibodies to CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD45RO (UCHL1), and CD25 (M-A251; BD Biosciences, San Jose, CA). Following incubation, OptiLyse B (Immunotech, Marseille, France) was added to each sample. Cells were reincubated at room temperature for 15 minutes and diluted with distilled water. Samples were analyzed within 48 hours on a FACSVantage SE flow cytometer (BD Biosciences). Data analysis was done using BD Flojo software.

Fluorescence-activated cell sorting analysis of tumor. Tumor samples were subjected to overnight digestion at room temperature in 0.1% collagenase (Sigma, St. Louis, MO). Following digestion, RBCs were lysed with 8.4 mg/mL NH₄Cl (Sigma). Cells were washed, counted, and labeled with biotinylated anti-(α)-CD45 (H360; BD Biosciences), followed by incubation with antibody microspheres (Miltenyi Biotec, Auburn, CA) and positive selection using AUTOMACS (Miltenyi Biotec). Enriched CD4+ cells (leukocytes) were subsequently stained with the same antibodies as those for whole blood. Cells were analyzed as above.

T<sub>reg</sub> retrieval from leukapheresis. Leukapheresis samples were diluted, underlayered with Ficoll (Histopaque 1077, Sigma), and spun for 25 minutes. Interphases were collected, washed extensively, and subjected to a 2-hour adherence step to remove monocytes. Nonadherent PBMCs were frozen until needed. Upon use, cells were rested overnight at 37°C, 5% CO₂. A CD4+ T-Cell Isolation kit II (Miltenyi Biotec) was used to isolate untouched CD4+ cells according to the instructions of the manufacturer. Briefly, a biotinylated antibody cocktail specific for non-CD4+ cells (CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRy/δ, and glycophorin A) was added, followed 10 minutes later by antibody microspheres. Samples were washed and run over AUTOMACS set to program DEPLETE. Nonlabeled fractions of CD4+ were labeled with phycoerythrin-α-CD25 (M-A251) and FITC-α-CD45RO (UCHL1) and sorted into CD25+CD45RO<sup>-</sup> (T<sub>reg</sub>) and CD25<sup>-</sup> populations on a FACSVantage SE flow cytometer. Purity of obtained populations was always >98%.

FOXP3 reverse transcription-PCR. Purified T<sub>reg</sub> and CD4+CD25<sup>-</sup> T cells were retrieved from leukapheresis samples as above. cDNA was synthesized from appropriate amounts of each cell type (stored at −137°C) by oligo(dT) with UMACS One-Step cDNA kit (Miltenyi Biotec) according to the protocols of the manufacturer. Human FOXP3 (hFOXP3) mRNA expression levels were measured by real-time PCR detected with SYBR green (Bio-Rad) according to the manufacturer. cDNA was synthesized with 200 pmol of each primer and 200 U of Taq polymerase (Invitrogen). The primers used were: hGAPDH forward primer (5′-CCATTCGAGCCAGGATG-3′) and reverse primer (5′-TCCTGGGCATCAAAGG-3′). For hGAPDH normalization, the primers used were: hGAPDH forward primer (5′-TGGCCATCCAGGATG-3′) and reverse primer (5′-TTGCTGGCGATCCG-3′). The PCR products were confirmed with melting curve analysis with the program DEPLETES. Negative fractions (CD4+CD25<sup>-</sup>) were collected for parallel culture with CD4+ T cells.

Results

T<sub>reg</sub> fraction is increased in patients bearing GBM. We determined the T<sub>reg</sub> fraction in the peripheral blood of patients with GBM. Based on recent studies of FOXP3 expression in T-cell subsets (22), T<sub>reg</sub> were defined as lymphocytes that possessed the plated alone in triplicate wells using either immobilized or soluble α-CD3 (OKT3) as stimulator at 2 μg/mL. To verify suppressive capacity among T<sub>reg</sub> (suppression assay), 5 × 10⁶ CD4+CD25<sup>-</sup> responders were plated alone or with varying doses of T<sub>reg</sub>, to a maximum ratio of 1:1 T<sub>reg</sub>/responders. Complete T-cell medium (CTM) consisted of RPMI + 10% FCS, supplemented with HEPES buffer, sodium pyruvate, penicillin/streptomycin, 1% l-glutamine, 10 μg/mL soluble phytohemagglutinin (PHA); or 0.1, 1, 5, 10, 20 μg/mL soluble concanavalin A (ConA) as stimulator.

CD4+ T-cell cultures. Untouched CD4+ T cells were cultured in triplicate in CTM (or in CTM with autologous serum substituted for FCS) at 5 × 10⁶ to 2 × 10⁷ per well in 96-well plates using either 0.1, 0.2, or 10 μg/mL soluble or plate-bound α-CD3 (OKT3); 0.1, 1, 5, 10, or 20 μg/mL soluble PHA; or 0.1, 1, 5, 10, 20 μg/mL soluble concanavalin A (ConA) as stimulator.

CD25<sup>-</sup> cell depletion from CD4+ T cells. CD25<sup>-</sup> depletion was done using CD25 Microbeads (Miltenyi Biotec) according to the instructions of the manufacturer. Briefly, CD4+ T cells were incubated with 20 μL beads per 10⁶ cells for 15 minutes, washed, and depleted over AUTOMACS using the program DEPLETES. Negative fractions (CD4+CD25<sup>-</sup>) were collected for parallel culture with CD4+ T cells.

Cytokine analysis. CD4+ T cells were cultured in 96-well plates with 0, 0.1, or 10 μg PHA as stimulator. At time points following 16 and 72 hours of culture, supernatants were harvested and processed in duplicate with a Bio-Plex Luminex 200 system (Bio-Rad) according to the instructions of the manufacturer. Supernatants were collected with antibody-conjugated beads, followed by incubation with biotinylated detection antibody. Reaction mixture was detected with streptavidin-phycocerythrin and analyzed on a Luminex 100 machine (Luminex Corporation, Austin, TX). Unknown cytokine concentrations were calculated by Bio-Plex Manager software using standard curves derived from a recombinant cytokine standard.

Intracranial tumor implantation. SMA-560 tumor cells were harvested in logarithmic growth phase. Tumor cells in PBS were then mixed 1:1 with 3% methylcellulose and loaded into a 250 μL syringe (Hamilton, Reno, NV). The needle was positioned 2 mm to the right of bregma and 4 mm below the surface of the skull at the coronal suture using a stereotactic frame (Kopf Instruments, Tujunga, CA). Cells (1 × 10⁶) were delivered in a total volume of 5 μL.

Statistical analysis. For comparisons of means among groups (i.e., T<sub>reg</sub> levels in patients versus healthy volunteers or proliferation levels in patients with and without increased T<sub>reg</sub> fraction), unpaired t tests were used. A paired t test was used to compare cytokine levels in patients before and after CD25 depletion. For correlation between T<sub>reg</sub> levels and proliferation levels, a Pearson coefficient was calculated using the null hypothesis that the coefficient was equal to zero. To compare proliferative response curves among groups, a generalized linear model for normal data that accounted for correlation of measurement replication within subjects was used. For in vivo studies, the survival experiences among defined experimental groups were compared with a log-rank test. Within each experimental group, the survival experience was described using the Kaplan-Meier estimator.
cell surface phenotype CD4+CD25+CD45RO+. Defining a surface phenotype permitted subsequent sorting for verification of function. Cells included under this definition showed appropriate levels of FOXP3 expression by reverse transcription-PCR (RT-PCR) and by intracellular staining for flow cytometry (78.10 ± 7.26% of CD4+CD25+CD45RO+ cells were FOXP3+; Fig. 1A and B). Conversely, our results also confirmed that FOXP3 resides specifically (95.58 ± 2.24% of FOXP3+ cells) within the CD25+CD45RO+ subset of CD4+T cells (Fig. 1B). Sorted CD4+CD25+CD45RO+ T cells from patients showed requisite in vitro anergy (Fig. 1C) and suppressive function (Fig. 1D) when entered into standard assays. Treg “fraction” was thus defined as the percentage of CD4+ T cells that coexpressed CD25 and CD45RO by flow cytometry. To reduce the contribution of potentially confounding variables introduced by surgery, Treg fraction was assessed in patients at preresection time points.

Treg fraction was determined in the peripheral blood of 20 patients with GBM (10 newly diagnosed, 10 recurrent, median age 50.5 years, range 31-67 years), and the mean value was compared initially to the mean fraction in blood obtained from 10 healthy, age-matched volunteers (median age 42.5 years, range 31-62 years). The proportion of Tregs in the peripheral blood of patients with GBM (15.94 ± 2.20%) was 2.63 times that found in the blood of normal volunteers (6.07 ± 0.39%, P = 0.004; Fig. 1A). This increase also corresponded to a significant shift in mean fluorescence intensity in the CD25 channel (P = 0.02, data not shown). Increased Treg fraction was not present in all patients as can be observed in the data distribution plot. A representative analysis is depicted in Fig. 2B. Of note, and as may be seen in the analysis, the majority of CD4+CD25+ T cells in both patients in healthy volunteers were CD45RO+. Overall, among the healthy volunteers enrolled, the mean percentage of CD4+CD25+ T cells that were CD45RO+ was 88.33% with a range from 69.84% to 98.80%. In patients with GBM, the mean did not differ significantly at 83.33% (P = 0.6673).

A protocol was also devised for detecting and quantifying Tregs among tumor-infiltrating lymphocytes (TIL) in GBMs. No significant difference between Treg fraction in blood and tumor was detected in any patient or across patients (data not shown). Using an unpaired t test, the P value for comparison of mean blood and tumor fractions across patients was 0.88. Despite a small sample size (n = 4), this test had >95% power to detect differences as small

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Verification of FOXP3 expression and Treg function. A, FOXP3 semiquantitative RT-PCR. CD4+CD25+CD45RO+ Tregs and CD4+CD25− lymphocytes were purified from leukaphereses obtained from eight patients with GBM and three healthy volunteers. RT-PCR for FOXP3 was done normalizing to GAPDH. Representative ratios of FOXP3 expression in Tregs to CD4+CD25− cells is depicted for one experiment analyzing levels in three patients and one healthy volunteer (done in triplicate). In all experiments, ratios in patients were greater than or equal to those in volunteers. B, confirmation that FOXP3 expression localizes to CD4+CD25+CD45RO+ T cells by intracellular flow cytometry. Representative panels from two healthy volunteers (n = 10) and three patients with GBM (n = 20). All panels depict CD4+ lymphocytes. FOXP3 expression is compared in CD25−CD45RO− (gray), CD25+CD45RO− (black), and CD25+CD45RO+ (white) subsets. The CD25−CD45RO− subset accounts for 95.58 ± 2.24% of cells demonstrating FOXP3 staining. [Note that CD25−CD45RO− and CD25+CD45RO− populations are given different priorities (i.e., shown in front or back) in top and bottom panels to more clearly show their degree of overlap.]

C, representative proliferation assay demonstrating relative Treg anergy. Tregs (1 × 10^5) or CD4+CD25− (1 × 10^5) cells were stimulated with anti-CD3 (OKT3). Proliferation after 72 hours was measured by [3H]thymidine uptake. Columns, mean counts over triplicate wells; bars, SD. D, representative suppression assay (done in triplicate for each of eight patients) demonstrating ability of Tregs in patients with GBM to inhibit T-cell proliferation. CD4+CD25− responder cells (5 × 10^4) and the indicated number of Tregs were plated in combination. Proliferation was measured as above. Points, mean counts over triplicate wells; bars, SD.
as 5%. This suggests that $T_{reg}$, although present in GBMs, are not concentrated at the tumor site relative to the systemic circulation.

To eliminate the possibility that the $T_{reg}$ fraction seen in blood was attributable to standard preoperative steroid treatments (23), patients receiving identical doses of pericraniotomy steroids but undergoing surgery for benign, non-glial intracranial tumors were similarly assayed preoperatively for $T_{reg}$ fraction ($n = 6$, median age 50.5 years, range 40-82 years). The mean fraction observed above in patients with GBM was significantly elevated over the mean value determined for patients with benign tumors (5.94 ± 0.89%), $P = 0.023$. Despite steroid therapy, the values in patients with benign tumors did not vary significantly from those in healthy controls ($P = 0.88$; Fig. 2A). $T_{reg}$ fraction in these patients also did not differ significantly from other patients with benign tumors not requiring steroid therapy (data not shown).

Reduction in absolute numbers of $T_{reg}$. To determine whether increased $T_{reg}$ fraction in patients represents a true expansion of this compartment, complete blood counting with manual differentiation and calculation of CD3+, CD4+, and CD8+ T-cell counts was done with blood collected from healthy controls and from patients with GBM at preoperative time points. A severe CD4+ T-cell lymphopenia was uncovered in the patients with GBM, who possessed a mean CD4+ T-cell count of 168.2 ± 50.0 cells/µL ($n = 8$) compared with a count of 668 ± 52.8 cells/µL determined for healthy volunteers ($n = 6$; $P < 0.0001$; reference range, 400-1,400 cells/µL; Fig. 3). Despite the elevated $T_{reg}$ fractions among CD4+ T cells in this subset of patients with GBM (mean 16.74%), such elevated fractions corresponded to an absolute $T_{reg}$ count of only 19.2 ± 2.7 cells/µL. This number was less than half that found among healthy volunteers (40.8 ± 4.8 cells/µL; $n = 6$, $P = 0.0011$), although $T_{reg}$ represented only 6.2% of CD4+ T cells in this control population.

Increased $T_{reg}$ fraction correlates with CD4+ T-cell proliferative defects. As we noted that cellular immune defects delineated for patients with malignant glioma show remarkable overlap with the typical consequences of $T_{reg}$ activity, we examined whether the uncovered elevations in $T_{reg}$ fraction might be linked to the manifestation of T-cell proliferative defects in patients with GBM. Leukaphereses were obtained from eight patients with GBM and four healthy controls. $T_{reg}$ fraction for each patient was determined, with significant elevations in $T_{reg}$ fraction defined $a priori$ as values exceeding 9.1% (mean normal value ± 2 SD). Of the eight patients with GBM, five possessed significant elevations in their peripheral blood $T_{reg}$ fractions (Fig. 4A, top, white columns).
The proliferative capacities of T-cell subsets from patients with GBM were assessed and compared with controls. To control for the existence of lymphopenia in patients and to therefore highlight only “intrinsic” proliferative defects within T-cell populations, equal numbers of patient and control cells were evaluated in a PHA-based proliferation assay.

Consistent with prior research, we found that patient T-cell proliferative defects were not present in all patients but, when present, were concentrated within the CD4+ subset. The bottom panel of Fig. 4A plots the individual CD4 proliferation values for the same controls and patients whose Treg fractions are depicted in the top panel. Interestingly, those patients possessing elevated Treg fractions (>2 SD above normal mean; range, 12.02-16.73%; \( P = 0.0003 \)), and these patients had CD4 proliferation levels significantly below those of controls (\( P < 0.0001 \)). The Pearson correlation coefficient for the plot is \(-0.794 \) (\( P = 0.019 \)). C, increased Treg fraction in patients is sufficient to elicit proliferative defects among normal CD4+ lymphocytes. Treg were isolated from leukaphereses taken from four healthy controls and mixed with constant numbers of autologous CD4+ cells to create Treg percentages equivalent to those representing an absence of Treg (0%), physiologic fraction of Treg (8%), or the mean Treg fraction in patients with GBM (16%). Cells were stimulated with anti-CD3. Increases in Treg fraction to those levels found in patients with GBM were sufficient to produce significant deficits in the ability of T cells to proliferate. Representative result of three experiments with each of four donors.

The proliferative capacities of T-cell subsets from patients with GBM were assessed and compared with controls. To control for the existence of lymphopenia in patients and to therefore highlight only “intrinsic” proliferative defects within T-cell populations, equal numbers of patient and control cells were evaluated in a PHA-based proliferation assay.

Consistent with prior research, we found that patient T-cell proliferative defects were not present in all patients but, when present, were concentrated within the CD4+ subset. The bottom panel of Fig. 4A plots the individual CD4 proliferation values for the same controls and patients whose Treg fractions are depicted in the top panel. Interestingly, those patients possessing elevated Treg fraction (mean, 14.06%; range, 12.02-16.73%; \( P = 0.0003 \)) showed significant CD4+ T-cell proliferative dysfunction (mean, 12,706 cpm; range, 7,297-20,949; \( P < 0.0001 \)), whereas those patients without Treg elevation (mean, 6.89%; range, 5.41-8.88%; \( P = 0.76 \); Fig. 4A, black columns) possessed CD4+ T cells that proliferated at normal levels (mean, 73,120 cpm; range, 62,638-90,712; \( P = 0.79 \)).

These results were suggestive of a correlation between elevations in Treg fraction and diminished CD4 proliferation in patients with GBM. To investigate this relationship in patients more directly, we plotted the respective Treg fraction and CD4 proliferation values for each patient against each other as a percentage of normal. Figure 4B reveals a strong negative correlation between Treg fraction and CD4+ T-cell proliferative capacity (Pearson coefficient \(-0.794 \), \( P = 0.019 \)). The predetermined threshold for Treg elevation is included on the plot and proved to be a remarkably accurate separator with regard to proliferative capacities.

In light of this correlation, we sought to determine whether creating a shift in the Treg fraction from normal levels to those levels observed in patients with GBM could, alone, lead to the appearance of proliferative defects among otherwise normal lymphocytes. To accomplish this, we added varying numbers of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM. The addition of Tregs to a fixed number of CD4+ lymphocytes obtained from normal donors to produce in vitro Treg fractions that corresponded to physiologic Treg levels and levels in patients with GBM.
correlate with the appearance of CD4 proliferative defects in patients with GBM, but also prove sufficient to elicit the same defects among normal lymphocytes.

**CD4**+ **T cells from patients function normally in the absence of T**reg**. T cells were harvested from the five patients above who exhibited substantial proliferative defects, as well as from three healthy controls. To eliminate the contributions of factors present in patient sera, the proliferative responses of lymphocytes from all individuals were tested at varying concentrations of PHA, anti-CD3 monoclonal antibody (OKT3), or ConA in medium containing FCS. The stimulators and doses chosen were those historically revealing the immunosuppressed phenotype (4, 7), and we confirmed substantial proliferative defects among CD4**+** T cells from patients with GBM (cumulative responses to PHA depicted in Fig. 5A). Significant differences were consistently observed at 5 and 10 μg PHA, but never at doses of ≤1 μg. Cumulative response curves of patients and controls were significantly different, P < 0.001. The persistence of dysfunction in the presence of FCS verified the existence of defects "intrinsic" to the CD4**+** T-cell compartment.

We next depleted CD25**+** cells from patient and control CD4**+** T cells and cultured equal numbers with the same stimulation profile. Depletion successfully erased the differences in proliferative responses originally seen among the two groups (P = 0.689; Fig. 5B). These proliferative defects were similarly reversed when CD25**−**-depleted T-cells from patients with GBM were cultured in medium containing autologous sera. As made evident by the cumulative data depicted in Fig. 5A and B, depletion commonly produced a moderate increase in the proliferative capacity of normal CD4**+** T cells while instigating a dramatic increase in the proliferative capacity of CD4**+** T cells from patients with GBM. These observations cohere with an elevated Treg fraction, and therefore elevated Treg contribution, among CD4**+** T cells in this patient population.

To eliminate the prospect that the proliferative defects observed among patients owed their etiology simply to dilution of responsive CD4**+**CD25**−** T cells with anergic Tregs, and not to suppressive effects of Treg per se, assays were conducted in which Treg were added back to fixed numbers of their own CD4**+**CD25**−** responders. The addition of Treg produced dose-dependent decreases in proliferative responses, demonstrating genuine suppression (a dilutional effect would have produced no difference in proliferation among fixed responder numbers). These assays are akin to those represented in Fig. 1D.

To determine the contribution of Treg to the cytokine dysregulation also typical among these patients, we examined the elaboration of IL-2, IL-4, IL-6, IL-10, IL-12 (p70 subunit), TNF-α, and IFN-γ by CD4**+** T cells from the patients above (as well as from the same healthy controls), when stimulated with or without prior removal of Treg. PHA was used for stimulation, and, initially, all cells were cultured in medium containing FCS. Levels of cytokine

![Figure 5](image_url)

**Figure 5.** Patient CD4**+** T cells function normally in the absence of Treg. A, levels of CD4**+** T-cell proliferation were assessed among cells from five patients with GBM possessing CD4 proliferative defects and from three healthy controls. CD4**+** T cells were cultured in equal numbers in the presence of varying concentrations of PHA, OKT3, or ConA and proliferation was assessed by [3H]thymidine incorporation. Patient CD4**+** T cells were cultured in medium containing FCS. Cumulative results of seven experiments with PHA as stimulator. Results were similar across all stimulators. B, assays in (A) were repeated following removal of CD25**+** cells. Differences in proliferation among patients and controls were erased ([P = 0.689]) even when patient cells were cultured in the presence of autologous serum. C, Treg depletion relieves Th2 shift in cytokine production. CD4**+** T cells were purified from patients with GBM (n = 5) and healthy controls (n = 3). Cells left nondepleted or depleted of CD25**+** cells were cultured in equal numbers using PHA as stimulator. Supernatants were collected and analyzed in duplicate for levels of IL-2, IL-4, IL-6, IL-10, IL-12 p70, TNF-α, and IFN-γ. Levels of production of each cytokine by patients were expressed as percentages of that by normal CD4**+** T cells to depict differences in profiles. Cumulative results from three experiments. Before depletion, patient CD4**+** T cells produce diminished levels of the Th1 cytokines IL-2, IL-6, IL-12 p70, TNF-α, and IFN-γ, but increased levels of the Th2 cytokines IL-4 and IL-10. This skew is almost completely eliminated upon depletion of CD25**+** cells (P values for shifts in production following depletion: IL-2, 0.0002; IL-6, 0.0974; IL-12 p70, 0.3264; TNF-α, 0.0017; IFN-γ, 0.0049; IL-4, N/A; IL-10, N/A). Postdepletion data is not available for IL-4 and IL-10 as levels of production were frequently below the level of detection (N/D) in both patients and volunteers following depletion (three of three experiments for IL-4 and two of three experiments for IL-10).
production by patients were expressed as percentages of production by normal CD4+ T cells to permit depiction of relative differences in cytokine profiles. As seen in Fig. 5C, before depletion, CD4+ T cells from patients with GBM elaborated reduced quantities of the Th1 cytokines IL-2, IL-6, IL-12p70, TNF-α, and IFN-γ but above-normal quantities of the Th2 cytokines IL-4 and IL-10, when compared with controls.

Among T-cell samples from patients with GBM that were depleted of CD25+ cells, however, production of the Th1 cytokines IL-2, IL-6, TNF-α, and IFN-γ came generally to match or exceed those levels produced by control CD4+ T-cells, similarly depleted (Fig. 5C). As with proliferation, shifts in the Th1 cytokine production among CD4+ T cells from controls were moderate, whereas more substantial changes were seen among CD4+ T cells from patients. The postdepletion shifts in the production of IL-2, IFN-γ, and TNF-α by T cells from patients were significant \((P = 0.0002, 0.0499, \text{and } 0.0017, \text{respectively})\). IL-12p70 was the only Th1 cytokine tested influenced externally by an elevated Treg fraction.

The postdepletion shifts in the production of Th2 cytokines proved dramatic for both patients and controls. Whereas IL-4 and IL-10 were initially elaborated in higher quantities by patient CD4+ T cells, depletion of CD25+ cells brought their levels in both patients and controls down to the limit of detection, such that no statistical comparisons could be made between the two populations (Fig. 5C). The net results of depletion, then, were elimination of Th2 cytokine production by both patient and control CD4+ T cells and the normalization of patient Th1 cytokine production.

Together, these data show that elevated fractions of Tregs undermine the proliferative capacities and cytokine elaboration profiles of CD4+ T cells from patients with GBM. The data also show that these cells are not actually intrinsically defective but instead are capable in vitro of essentially normal function when not influenced externally by an elevated Treg fraction.

**Treg depletion in vivo leads to glioma rejection.** We verified that Tregs in VM/Dk mice possess the appropriate traits reported for Tregs in in vitro functional assays. As CD45RO is not a murine phenotypic marker, Tregs were defined for this purpose as CD4+CD25+GITR+ T cells. Isolated CD4+CD25+GITR+ T cells from these mice expressed Foxp3, failed to respond to stimulation, and exhibited the expected dose-dependent capacity to suppress the proliferative responses of surrounding CD4+CD25- cells (data not shown). We also established our ability to successfully deplete Tregs from VM/Dk mice. A single dose of 0.5 mg anti-CD25 (PC61) delivered i.p. successfully depleted CD25+ cells from mice, and these levels did not recover for ~30 days (data not shown).

To assess the effects of Treg depletion when effected before any disruption of the blood-brain barrier, Treg depletion was initially evaluated in an SMA-560 tumor challenge model. SMA-560 is a malignant astrocytoma cell line derived from tumors that originated spontaneously in inbred VM/Dk mice. All mice \((n = 20)\) were challenged intracranially with 10,000 syngeneic SMA-560 astrocytoma cells. Treg depletion produced 50% long-term survivors with no evidence of tumor. Differences in survival curves are significant \((P = 0.0002)\).

**Figure 6.** Treg depletion in vivo extends survival and permits tumor rejection in a murine model of intracranial glioma. A, VM/Dk mice \((n = 10 \text{ per group})\) were left nondenpleted or were depleted of Tregs with i.p. PC61 on day -4. On day 0, all mice were challenged intracranially with 10,000 syngeneic SMA-560 astrocytoma cells. Treg depletion produced 50% long-term survivors with no evidence of tumor. Differences in survival curves are significant \((P = 0.0002)\). B, effects of Treg depletion in a therapeutic model. Depleted mice \((n = 7)\) received i.p. PC61 3 days following tumor implantation, when tumor was established. Treg depletion significantly extended median survival \((P = 0.0003)\) and produced nearly 15% long-term survivors with no evidence of tumor.

The ability of Treg depletion to extend survival was next evaluated in a more stringent therapeutic model of established tumor. Again, all mice \((n = 14)\) were implanted intracranially with 10,000 SMA-560 cells. In this instance, however, 50% of the mice were depleted of Tregs with PC61 delivered in a single systemic dose 3 days pursuant to tumor implantation, after tumor had become established. Despite the stringency of the model, median survival was extended nearly 30% \((P = 0.0003)\), and ~15% of mice survived long-term with no subsequent evidence of tumor (Fig. 6B). Taken with the results of the tumor challenge experiments, these data imply that a reasonable physiologic response against intracranial tumor exists but may fail in the presence of Treg.

**Discussion**

The initial descriptions of impaired cellular immunity in patients with malignant glioma date to the 1970s (4, 24–26). Lymphocyte
dysfunction has since been progressively narrowed to the CD4+ T-cell subset (6), which exhibits substantial defects when cultured en masse. Attempts to understand and reverse such dysfunction have continued unremittingly.

It is therefore a dramatic finding that upon removal of its Treg constituent, the remaining CD4+ compartment of patients with GBM functions normally in vitro. This shows that "intrinsic" CD4+ T-cell functional deficits are neither cell inherent nor irreversible. Instead, they appear to be the product of an elevated Treg fraction and may be abrogated simply via depletion of Treg cells. We have not overlooked the effects of factors present in patient serum; rather, we have focused on and uncovered the source of those substantial defects that remain in their absence. Whereas these intrinsic defects remained erased when Treg-depleted cells were cultured in autologous sera, such sera were not extensively characterized and were retrieved from patients relatively early in their disease course. It remains possible that sera obtained from patients at later stages of disease would have had more substantial effects.

To our knowledge, absolute Treg counts have not previously been reported in patients with malignancy. The increased Treg levels reported in similar studies (18–21) more truly represent what we have termed here the Treg compartment. Consequently, it is unclear whether the elevated Treg levels previously reported among other cancer populations represent a veritable expansion of this compartment in vivo. We show, however, that Treg substantially compromise T-cell function despite being reduced in absolute number in vivo. What appears of more pertinence than Treg numbers, then, is the fraction that they represent of the surrounding CD4 compartment. In our patients, this fraction is significantly increased, and this increase is what correlates with T-cell dysfunction.

We are also the first to report profoundly reduced CD4+ T-cell counts in preresection patients with GBM. These patients exhibited mean CD4 counts below 200 cells/μL, the demarcation for progression to AIDS in HIV-infected individuals. The severity of this lymphopenia is perplexing, given the overwhelming absence of systemic disease in this population. Another group has reported diminished CD4 counts in patients with primary brain tumors who were already undergoing radiotherapy (27). As cranial radiotherapy is a known contributor to myelosuppression (28), this previous observation of an increased fraction of Tregs whose most common identifying marker is the α chain of the high-affinity IL-2R (CD25).

Upon closer examination, however, these previous studies report only IL-2R expression on lymphocytes following mitogenic stimulation, and no data are offered concerning resting levels on freshly isolated cells. As CD25 is also a T-cell activation marker, it is these preactivation levels that more accurately depict Tregs. Interestingly, one study in patients with malignant glioma, published before the current Treg literature, measured CD25 levels on freshly isolated TIL and reported that these levels were markedly elevated (9).

Our results translate into a potential for therapeutic benefit, as Treg depletion in mice proves permissive for glioma rejection in the intracranial compartment even in instances of established tumor. This rejection is notably effected following systemic delivery of antibody and in the absence of additional therapeutic intervention. A salient implication is that in the absence of Tregs, the physiologic immune response possesses some capacity to reject tumor located in the immunologically privileged central nervous system. Our data suggest that a systemic immune response to tumors in the central nervous system occurs and that peripheral Tregs are important in attenuating this response. Tumors situated intracranially are, in turn, clearly capable of modulating systemic immunity and may derive some of their success in this endeavor from alterations elicited in the Treg fraction.

Acknowledgments

Received 10/19/2005; revised 1/9/2006; accepted 1/19/2006.

Grant support: NIH Specialized Programs of Research Excellence grants 1P50 CA108786 (D.D. Bigner and J.H. Sampson), RO1 CA09722 (J.H. Sampson), and MSTP T32 GM-07171 (P.E. Fecchi), and grants from the Brain Tumor Society (J.H. Sampson) and Accelerate Brain Cancer Cure Foundation (J.H. Sampson and D.D. Bigner). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

2. McVicar DW, Davis DF, Merchant RE. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppres-


Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/6/3294

Cited articles
This article cites 36 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/6/3294.full.html#ref-list-1

Citing articles
This article has been cited by 73 HighWire-hosted articles. Access the articles at:
/content/66/6/3294.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.